Biliary cast syndrome following liver transplantation: Predictive factors and clinical outcomes

Niraj V. Gor, Ronald M. Levy, Joseph Ahn, Dmitriy Kogan, S. Forrest Dodson, Stanley Martin Cohen – 29 September 2008 – Biliary cast syndrome (BCS), the presence of biliary casts and debris causing biliary obstruction, occurs in 4%‐18% of orthotopic liver transplant (OLT) recipients. Potential consequences include cholangitis and graft damage or loss. Limited data exist regarding the etiology and outcomes of BCS. The purpose of this study was to evaluate donor and recipient risk factors and determine the impact of BCS.

Risk of malignant neoplasms after liver transplantation: A population‐based study

Fredrik Åberg, Eero Pukkala, Krister Höckerstedt, Risto Sankila, Helena Isoniemi – 29 September 2008 – Posttransplant malignancies have become a serious long‐term complication after liver transplantation. Our aim was to compare the incidence of posttransplant cancers with national cancer incidence rates. The study included all Finnish liver transplant patients transplanted at the Helsinki University Central Hospital between 1982 and 2005. The cohort was linked with the nationwide Finnish Cancer Registry.

Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma

Mauricio Silva, Angel Moya, Marina Berenguer, Fernando Sanjuan, Rafael López‐Andujar, Eugenia Pareja, Rodrigo Torres‐Quevedo, Victoria Aguilera, Eva Montalva, Manuel De Juan, Angelo Mattos, Martín Prieto, José Mir – 29 September 2008 – Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community.

High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation

Minna Ilmakunnas, Eija M. Tukiainen, Ari Rouhiainen, Heikki Rauvala, Johanna Arola, Arno Nordin, Heikki Mäkisalo, Krister Höckerstedt, Helena Isoniemi – 29 September 2008 – High mobility group box 1 protein (HMGB1), a cytokine actively secreted by phagocytes and passively released from necrotic cells, is an inflammatory mediator in experimental hepatic ischemia/reperfusion injury. We characterized its expression in human liver transplantation.

Subscribe to